Fig. 6
From: Treatment approaches for idiopathic retroperitoneal fibrosis: a systematic review with meta-analysis
Forest plot for the outcome “clinical improvement”. *Follow-up months as a median; **Follow-up months includes follow-up period from secondary retroperitoneal fibrosis patients (Keehn et al: 85% of patients were idiopathic; Elashry et al: Outcome and baseline characteristics are separately reported for idiopathic retroperitoneal fibrosis patients); Trt treatment, n patient number, AZA Azathioprine, CST Corticosteroids, MMF Mycophenolate Mofetil, RTX Rituximab, TMX Tamoxifen, UL Ureterolysis